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Rheumatoid arthritis (RA) is characterized by synovial inflammation and hyperplasia. Fibroblast-like synoviocytes (FLSs) are
apoptosis-resistant and contribute to the pathogenesis of RA by producing cytokines and proteolytic enzymes, which degrade
the extracellular matrix. We evaluated the proapoptotic and anti-inflammatory activity of the small molecule Smac127 on RA-FLSs
cultured in synovial fluid (SF), in order to reproduce the physiopathological environmental characteristic of RA joints. In this
context, Smac127 induces apoptosis by inhibiting apoptosis proteins (IAPs). This inhibition activates caspase 3 and restores the
apoptotic pathway. In addition, Smac127 induces a significant inhibition of the secretion of IL-15 and IL-6, stimulation of pannus
formation, and damage of bone and cartilage in RA. Also the secretion of the anti-inflammatory cytokine IL-10 is dramatically
increased in the presence of Smac127. The cartilage destruction in RA patients is partly mediated by metalloproteinases; here we
show that theMMP-1 production by fibroblasts cultured in SF is significantly antagonized by Smac127. Conversely, thismolecule has
no significant effects on RANKL andOPGproduction. Our observations demonstrate that Smac127 has beneficial regulatory effects
on inflammatory state of RA-FLSs and suggest a potential use of Smac127 for the control of inflammation and disease progression
in RA.
1. Introduction
Rheumatoid arthritis (RA) is characterized by synovial
inflammation and hyperplasia, autoantibodies production
(rheumatoid factor and anti-citrullinated protein antibodies
[ACPA]), and cartilage and bone destruction. Numerous
lines of evidence support the potential contribution of
fibroblast-like synoviocytes (FLSs) to the pathogenesis of
chronic arthritis [1, 2]. In the joints, RA-FLSs display a
constitutive proinflammatory phenotype that also persists in
tissue culture in the absence of exogenous stimuli [3–5]. This
is a tumour-like phenotype that transforms FLSs from fairly
“innocent” mesenchymal cells to destructive aggressors,
characterized by a number of unique and remarkable features,
such as expression of adhesion molecules and mediators,
contributing directly to local cartilage destruction and to
the chronicity of synovial inflammation [6, 7]. Resistance
to apoptosis has also been associated with this specific
phenotype of RA-FLSs [8], there is an imbalance between cell
death and survival in RA-FLS [9], and themicroenvironment
also contains, besides the proinflammatory cytokines, factors
contributing to induce resistance to apoptosis [10]. It has
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been suggested that a reduced rate of programmed cell
death may provide an explanation for synovial hyperplasia
and contribute to invasiveness of RA-FLSs. In the apoptosis
resistance are involved the inhibitors of apoptosis proteins
(IAPs), a diverse family of proteins that have been implicated
as regulators of apoptosis, mitosis, and inflammation [11–13].
However, to date, the overwhelming majority of studies have
focused on the ability of these proteins tomodulate apoptosis,
particularly in the context of TNF receptor engagement,
and few studies have explored the role of the IAPs in the
production of proinflammatory mediators. Because TNF is a
major driver of inflammation in response to infection, as well
as in the context of inflammatory diseases [14, 15], the role of
IAPs in shaping TNF-dependent inflammatory signalling is
an important unresolved question. Recent evidence indicates
that cIAP-1 and cIAP-2 play particularly influential roles in
repressing TNFR-induced cell death signals. These proteins
are characterized by the presence of one to three baculoviral
IAP repeat (BIR) domains responsible for the antiapoptotic
activity of IAPs because they bind to caspases 3, 7, and
9 and prevent assembly of caspases 8 and 10 [16]. Smac,
an endogenous proapoptotic protein, upon release from
the mitochondria, binds and antagonizes several members
of the IAP family including XIAP, cIAP-1, and cIAP-2.
Numerous synthetic Smac mimetic compounds resemble
the Smac N-terminal AVP1 sequence and bind to the BIR3
domain on XIAP and IAPs. These compounds also promote
IAP ubiquitination and subsequent degradation [17, 18] and
endogenous TNF alpha lowers maximum peak bone mass
and inhibits osteoblastic Smac activation through NF-𝜅B.
In our previous work, we showed that the Smac mimetic
Smac066 (Figure 1; X = H) was able to induce apoptosis in
RA-FLSs, proving its activity also in inflammatory diseases.
In the present study we evaluated the proapoptotic effect
of a more potent analogue, Smac127 (Figure 1; X = CF
3
).
While Smac66 and Smac127 showed similar binding potency
on BIR3 domains from XIAP and cIAP-1 (Figure 1) and
were equally stable in biological media, the trifluoromethyl
substituent in Smac127 increased its lipophilicity and facil-
itated its permeation through cell membranes (indirectly
measured by ≈30-fold increase in cytotoxicity for Smac127
versus Smac66 (Figure 1)). Finally, we demonstrated the anti-
inflammatory activity of Smac127 on RA-FLSs cultured in
tissue medium alone or in the presence of RA synovial
fluid.
2. Materials and Methods
2.1. Smac Mimetic Compound. The synthesis of Smac127 was
carried out as described elsewhere [19, 20]. Smac127 was
dissolved and diluted in distilled sterile water for in vitro
administration.
2.2. Synovial Fluid Samples and Fibroblast-Like Synoviocytes.
All samples of liquid and/or synovial membrane were taken
from the materials considered waste during arthrocentesis
or surgery, collected by a single team at Ist Division. Local
Ethical Committee of A.O.Gaetano PiniOrthopedic Institute
and University of Milan approved whole study (approved on
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Figure 1: Smac066 and Smac127: chemical structures, cell-free
affinity for IAPs, and cytotoxicity against MDA-MB-231 cells.
27March, 2012). All patients signed informed consent to take
part in the study.
2.3. Synovial Fluid Samples. SF was directly aspirated from
the joints of RA patients; the fluid was collected into hep-
arinized tubes and spun at 1000×g for 10min. The acellular
portion of SF was stored at −80∘C before use. We used pools
composed of 10 RA patients’ fluid to reduce the variability in
responses between the different fluids. SF pool was used at the
final dilution of 1 : 8 in culture medium.
2.4. Fibroblast-Like Synoviocytes. Synovial tissue was ob-
tained from patients with RA (𝑛 = 22) during joint
synovectomies. Human synovial tissues were digested with
collagenase in Dulbecco’s Modified Eagle Medium (DMEM)
(Euroclone, Pero, Italy) for 2 hrs at 37∘C to isolate synovio-
cytes. Dissociated cells were then centrifuged at 1000×g,
suspended in DMEM supplemented with 10% FetalClone 1
serum (FCS) (Thermo Scientific, USA), 2mM L-glutamine,
100 units/mL of penicillin, and 100𝜇g/mL streptomycin
(Euroclone, Pero, Italy), and plated. After overnight culture,
nonadherent cells were removed, and adherent cells were cul-
tivated in DMEM supplemented with 10% FCS. The cultures
were kept at 37∘C in 5% CO
2
and the medium was replaced
every 3 days. The purity of the cells was tested by flow-
cytometric analysis using phycoerythrin-conjugated anti-
CD14 (Pharmingen, San Diego, CA, USA), fluorescein isoth-
iocyanate phycoerythrin-conjugated anti-CD3, anti-CD19,
and anti-Thy-1 (CD90) monoclonal antibodies (R&D Sys-
tems, Minneapolis, MN). A FACS Calibur flow cytometer
(488Ex/620Em) (Becton Dickinson, San Jose, CA, USA) was
used for the analysis. At passage 3, the cells weremorphologi-
cally homogeneous and exhibited the appearance of FLS, with
typical bipolar configuration under inversemicroscopy.Most
cells (>98%) expressed the surface marker for fibroblasts
(Thy-1) and were negative for the expression of CD3, CD19,
and CD14. Synoviocytes from passages 3–8 were used in each
experiment.
2.5. Apoptosis Assay. We assessed apoptosis in RA-FLSs cul-
tured in tissue medium alone or in SF (1 : 8 dilution in culture
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medium) for 5 days, in the presence/absence of Smac127
(15 𝜇M) for 24 hrs. Apoptotic cells were detected with the
Annexin V-FITC apoptosis detection kit (Abcam, Cam-
bridge, UK), according to themanufacturer’s instructions. All
samples were analysed with a FACS Calibur flow cytometer.
FITC-conjugated Annexin V emission was collected in the
FLH-1 channel, and propidium iodide (PI, for detecting
necrotic or dead cells) emission was collected in the FLH-3
channel. Data were analysed with Cell Quest software. The
percentage of apoptosis was calculated, considering cells in
both early (Annexin+ PI−) and late apoptosis (Annexin+ PI+).
2.6. Western Blots. RA-FLSs were grown in culture medium
or in SF (1 : 8 dilution in culture medium) for 5 days. Smac127
(15 𝜇M)was added to the cultures 48 hrs before sacrificing the
cells for IAPs detections, while for caspase detection Smac127
was added to the culture in medium alone 6 hrs before the
sacrifice and to the culture in medium supplemented with
SF 18 hrs before the sacrifice. Staurosporine (20 𝜇M) (Sigma-
Aldrich, St. Louis, MO) was used as proapoptotic positive
control. Cells were lysed in lysis buffer and protein concentra-
tion was measured by the BCA method (Thermo Scientific,
USA) according to the manufacturer’s instructions. The cell
lysates were separated by SDS-PAGE on 4–12% Tris-HCl
precast gels for IAPs detection, or by 10% Tris-HCl precast
gels for caspase 3 detection (Life Technologies, Carlsbad,
CA), and transferred onto nitrocellulose membranes (Life
Technologies, Carlsbad, CA). The membranes were blocked
for 3 hrs with 5% nonfat dry milk (Lab Scientific) in PBS 0.1%
Tween-20 (Sigma-Aldrich, St. Louis, MO) and probed with
primary antibody overnight at 4∘C. The primary antibodies
usedwere cIAP1 (1 : 600) (R&DSystems,Minneapolis), cIAP2
(1 : 600) (BDPharmingen,MA,USA) andXIAP (1 : 400) (Cell
Signaling Technology, Europe), and anticaspase 3 mouse
monoclonal antibody (2 𝜇g/mL) (Enzo life Sciences, USA),
whereas 𝛽-actin (1 : 4000) (Sigma-Aldrich, St. Louis, MO)
was used as the loading control. Secondary antibodies were
conjugated to horseradish peroxidase (Thermo Scientific,
USA) and the gels developed using Western Lightning
Plus ECL (PerkinElmer, OH, USA). Densitometry was per-
formed using ImageJ software (National Institutes of Health,
Bethesda, USA).
2.7. Cytokine and Proliferation Assay. RA-FLSs were cultured
in culturemedium alone or in the presence of SF (1 : 8 dilution
in culture medium) for 5 days and treated with Smac127
24 hrs before the sacrifice; then the cells were fixed and
permeabilized. To avoid nonspecific binding, the samples
were saturated with LI-COR Odyssey Blocking Buffer for
2 hrs withmoderate shaking.The plate was washed four times
with washing solution (PBS added with 0.1% Tween-20). RA-
FLSs were incubated with 50 𝜇L of several primary mouse
monoclonal antibodies (anti-human IL-15 (15 𝜇g/mL), IL-6
(15 𝜇g/mL), and IL-10 (15 𝜇g/mL) (Peprotech, Rocky Hill, NJ,
USA)) (anti-MMP1(1 : 40), RANKL (1 : 70), and OPG (1 : 15)
(Novus, Italy)). After 2.5 hrs, the plate was washed 5 times
with PBS + 0.1% Tween-20 and incubated for 1 hr with goat
anti-mouse IRDye™ 800CW labeled secondary antibodies
(1 : 800 dilution; LI-COR) and with CellTag 700CW (1 : 500;
LI-COR) for cell number normalization.The negative control
was obtained incubating cells with secondary antibody alone.
After 5 washes with PBS + 0.1% Tween-20, the plate
was scanned simultaneously at 700 nm and 800 nm using
the Odyssey infrared imaging system (LI-COR Bioscience).
The fluorescently labelled IRDye 800CW secondary anti-
body was used for detection of a specific cytokine in the
800 nm channel, and two fluorescent cell stains are used in
combination in the 700 nm channel to normalize for well-
to-well variations in cell number. CellTag 700 Stain is a
near-infrared, fluorescent, nonspecific cell stain that provides
accurate normalization to cell number.The stain accumulates
in both the nucleus and cytoplasm of permeabilized RA-FLS.
2.8. Statistical Analysis. Statistical analysis was performed
using Student’s test for matched pairs. Differences with a con-
fidence level of >95% were considered statistically significant
(𝑝 < 0.05). SPSS 21 (IBM) program will be used.
3. Results
In our previous paper we showed that Smac066 induced
apoptosis in RA-FLSs [21]; now here we studied Smac127.
Smac66 and Smac127 showed similar binding potency on
BIR3 domains from XIAP and cIAP-1 (Figure 1) and were
equally stable in biological media, but the trifluoromethyl
substituent in Smac127 increased its lipophilicity and facil-
itated its permeation through cell membranes—indirectly
measured by ≈30-fold increase in cytotoxicity for Smac127
versus Smac66, which is endowed with greater lipophilicity
and intracellular uptake. Since Casnici et al. emphasized
the importance of using SF from RA patients in “in vitro”
studies involving RA cells, in order to reproduce faithfully
the physiopathological environment of RA joints [22], we
tested Smac127 on RA-FLSs cultured in SF as well as in
tissue medium alone. Our new Smac mimetic compound
induced a significant inhibition of cell growth, although lower
when cells were cultured in SF (Figure 2). Then, we assessed
apoptosis in RA-FLSs cultured in tissue medium alone or
in SF, in the presence/absence of Smac127. After 5 days of
culture, the addition of Smac127 before the Annexin V test
(24 hrs) induced apoptosis and the percentage of apoptotic
cells observed in the cultures with SF was lower than those
with medium alone but remained significant. Taking into
consideration that in the presence of SF a lower percentage of
apoptotic cells was initially present than whenmedium alone
was used, probably due to the presence in SF of antiapoptotic
factors, the induction of apoptosis by Smac127 was similar in
both culture conditions (Figure 3).
Since IAPs are expressed at high levels in RA-FLSs and
Smac127 should downregulate these proteins and promote
the induction of cell death, we analysed the effect of Smac127
on these proteins. As shown in Figure 4, Smac127 down-
regulated cIAP1, cIAP2, and XIAP expression in RA-FLSs
cultured in tissue medium alone or in the presence of SF.
As reported in Figure 5, Smac127 could also promote both
the proteolytic activation of procaspase 3 and the enzymatic
activity of mature caspase 3. As a positive control, RA-FLSs
were incubated with the apoptosis inducer staurosporine.
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Figure 2: Smac127 inhibits the proliferation in fibroblast-like
synoviocytes (FLSs) derived from patients with rheumatoid arthritis
(RA). RA-FLSs were cultured in tissue medium alone (TM) or in
synovial fluid (SF). CTRL are the cells without Smac127. “Smac”
are the cells after the addition of Smac127 (15 𝜇M) for 24 hrs. The
data are generated with Odyssey infrared platform. In Cell Western
with 700 channels detecting cell proliferation, we detected cytokine
production with 800 channels. Results are expressed as the mean
percentage± SD from four individual experiments. ∗𝑝 < 0.05 versus
CTRL or SF.
Furthermore, in RA joints, an imbalance between pro- and
anti-inflammatory cytokine activities favours the induction
of autoimmunity, of chronic inflammation, and thereby of
joint damage [15]; therefore, we studied the effects of Smac127
on the modulation of the cytokines expression. In particular,
we analysed the production of inflammatory cytokines IL-
15 and IL-6 and that of the anti-inflammatory cytokine
IL-10. All of these cytokines are known to be involved in
RA pathology. As reported in Figure 6, Smac127 induced
a significant inhibition on the secretion of IL-15 and IL-6
while the production of anti-inflammatory IL-10 dramatically
increased, both in cells cultured in tissue medium alone
and in presence of SF (Figure 6). Immune cells and FLSs
are the main source of receptor activator of nuclear factor
kappa-B ligand (RANKL) in pathological conditions such
as arthritic RA joints. The cartilage destruction in RA
patients is partly mediated by metalloproteinases secreted
by activated synoviocytes and chondrocytes [23]. For this
reason we also explored the influence of Smac127 on the
RA-FLSs production of metalloprotease 1 (MMP-1), RANKL,
and osteoprotegerin (OPG), involved in bone resorption
characteristic of RA pathology (Figure 6). The maximum
production of MMP-1 occurred when the fibroblasts were
cultured for 5 days in SF, and this productionwas significantly
antagonized by Smac127 (Figure 6). Conversely, Smac127
treatment did not influence the secretion of RANKL and
OPG.
4. Discussion
IAPs are overexpressed in RA-FLSs and contribute to their
expansion, inflammation, and disease progression [24] and
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Figure 3: Smac127 induces apoptosis in fibroblast-like synoviocytes
(FLSs) derived from patients with rheumatoid arthritis (RA). RA-
FLSs were cultured in the presence of tissue medium alone (TM)
or in synovial fluid (SF) for 5 days. Smac127 (15 𝜇M) was added
for 24 hrs. Apoptosis was detected by Annexin V test. Results
are expressed as the mean percentage ± SD from five individual
experiments. ∗𝑝 < 0.05 versus CTRL or SF.
small molecules that disrupt the binding of IAPs with their
functional partners, such as caspases, should restore the
cancer cell’s apoptotic response to proapoptotic stimuli [24,
25]. RA-FLSs are resistant to apoptosis and this resistance
and the increased proliferation of FLSs might contribute
to the pathogenesis of RA [8, 9]. In a previous paper, we
demonstrated, for the first time, that FLSs are sensitive
to Smac mimetics [21]; here we evaluated the effects of
more lipophilic, cell-permeable Smac127. Indeed, the triflu-
oromethyl substituent in Smac127 increased its lipophilicity
and facilitated its permeation through cell membranes. Cas-
nici et al. demonstrated that “in vitro” RA studies performed
in the presence of SF in the culture medium recreate the
physiopathological microenvironment of RA [22], because
the composition of SF in RA pathology is very complex
and strongly influences the microenvironment of joints.
Furthermore, SF may contain many antiapoptotic factors
that could reduce cells apoptosis. Thus, it was important to
evaluate how Smac127 acted on RA-FLSs cultured in the
presence of SF in the culture medium. To this purpose, we
used a pool of SF fromRApatients tominimize the variability
in responses among the different individual SF samples. In
this study we showed that Smac127 induced a significant
inhibition of FLSs growth and induced apoptosis in RA-FLSs
cultured in tissue medium or in SF (Figures 2 and 3). The
percentage of apoptosis in cells cultured in SF was lower than
in cells cultured in tissue medium alone, probably because of
the presence in the SF of antiapoptotic factors. In our previous
study [21] we showed that resistance to apoptosis in RA-FLSs
depends on upregulation of IAPs. Indeed, Figure 4 shows that
our molecule significantly inhibits the expression of IAP1,
IAP2, and XIAP in RA-FLSs cultured in presence of both
tissue medium and medium added with SF. We propose that
administration of Smac127 could lead to rapid induction and
proteasomal degradation of cellular IAPs and to the inhibi-
tion of canonicalNF-𝜅Bpathway [17], leading to upregulation
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Figure 4: Smac127 inhibits the IAP proteins in RA-FLSs cultured in tissue medium or in synovial fluid. RA-FLSs were grown in tissue
medium (TM) or in synovial fluid (SF). Smac127 (15 𝜇M)was added for 48 hrs. (a) Immunoblots show the detection of cIAP1 (72 kDa), cIAP2
(70 kDa), and XIAP (55 kDa). 𝛽-actin was used as a loading control (42 kDa). (b) Densitometric analyses of the immunoblots show the ratio
of IAPs/actin protein expression ± SD of the mean from four independent experiments. #𝑝 < 0.05 indicates statistically significant differences
compared to untreated RA-FLSs.
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Figure 5: Smac127 induces caspase 3 activation. Western blot analysis shows the effect of Smac127 on caspase 3 in extracts from human
fibroblast-like synoviocytes (FLSs) derived from patients with rheumatoid arthritis cultured in TM (a) or in SF for 5 days (b). Levels of cleaved
caspase 3 were measured in RA-FLSs untreated (CTRL) or treated with Smac127 (15𝜇M) or treated with the apoptosis inducer staurosporine
(stauro). Cells cultured in tissue medium alone were incubated for 6 hrs, whereas cells grown in the presence of SF were incubated for 18 hrs;
staurosporine 20 𝜇Mwas the positive control.
of other survival proteins includingBcl-2 andBcl-xL. [26, 27].
Smac127 enhanced the autoubiquitination of cIAPs, leading
to their rapid destruction and thus allowing the activation
of caspases inhibited by IAPs, when RA-FLSs were cultured
either in tissue medium (Figure 5(a)) or in SF (Figure 5(b)).
Probably, Smac127 disrupts IAP interaction with caspases or
decreases intracellular levels of IAPswith distinct approaches,
such as autoubiquitination-induced degradation, damaging
the translation of IAP proteins, or inhibiting the transcription
of IAPs. When cIAP1/2 are eliminated by IAP antagonists,
a brief activation of the classical pathway NF-𝜅B occurs,
presumably due to transient scaffolding from autoubiquiti-
nation, resulting in a short surge of TNF alpha expression,
although TNF-independent apoptosis has been reported [24,
28, 29].
The overgrowth of FLSs results in the formation of typical
RA pannus, which erodes surrounding bone [23], and in
the production of proinflammatory cytokines, released by
infiltrating mononuclear cells and lining synoviocytes, thus
promoting and sustaining inflammation by both autocrine
and paracrine pathways [29, 30], and the persistent imbalance
between pro- and anti-inflammatory mechanisms leads to
chronic inflammation and subsequent joint destruction.
IAPs influence the production of multiple inflammatory
mediators, which are not only inhibitors of apoptosis, and
here we demonstrated that Smac127 was able to inhibit IL-15
production in all tissue culture conditions. IL-15 is a potent
proinflammatory cytokine, constitutively expressed on the
surface of RA-FLSs, that plays a role in the pathogenesis of
RA.
The blockade of IL-15 secretion by Smac127 is an impor-
tant goal because it breaks the proinflammatory loop and
decreases the resistance to apoptosis of FLSs [31]. The levels
of IL-6 were very high in RA-FLSs cultured in the presence
of SF, which reproduce the microenvironment within the
inflamed joints, and this is consistent with the hypothesis of
the presence of several prosurvival and proliferative factors,
secreted by cells locatedwithin the joint [32, 33]. Interestingly,
we found that Smac127 also inhibited IL-6 production when
RA-FLSs were cultured both in tissue medium and in the
presence of SF.
The intense synovial cell hyperplasia and proliferation are
associated with a compensatory anti-inflammatory response
characterized by the production of soluble TNF recep-
tors, transforming growth factor (TGF-𝛽), IL-1 receptor
antagonist (IL-1RA), and IL-10. Particularly, levels of IL-
10 are elevated in serum and SF of patients with RA and
biologically significant quantities of functionally active IL-
10 are released in the suspensions of rheumatoid synovial
cell cultures [34–36]. Our results demonstrate that Smac127
significantly increased the production of IL-10 (Figure 6).
This result is interesting because this cytokine has a dual anti-
inflammatory activity, as, on the one hand, it decreases the
secretion of proinflammatory cytokines IL-15 and IL-6 and
on the other hand it stimulates its own secretion in RA-FLSs,
particularly when cultured in SF. Here we did not investigate
whether the stimulation of IL-10 secretion by Smac127 was
responsible of the downregulation of IL-15 and IL-6 or if such
downregulation is a direct effect of Smac127. The synergistic
interactions among the different cytokines in the inflamed
joint enhance the production of MMPs and subsequent joint
destruction.MMPs determine the timing, the amplitude, and
the combination of molecular signals that are released within
a tissue, and crucially influence the availability of cell death
or cell protective cues in the microenvironment, thereby
affecting the outcome of an inflammatory challenge [37].
Since the regulation of MMPs becomes aberrant in immune
cells inmany human inflammatory and autoimmune diseases
[37, 38], we also evaluated the effect of Smac127 on MMP-
1 production. We observed that it reduced MMP-1 levels
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Figure 6: Cytokine modulation in RA-FLSs. IL15: RA-FLSs were grown in tissue medium (TM) or in synovial fluid (SF) for 5 days. Smac127
(15𝜇M) was added for 24 hrs. The data were generated with Odyssey infrared platform. In Cell Western with 800 channels we detected the
cytokine production. Data are expressed as In Cell Western relative data (ICW relative). We analysed the production of IL-15, IL-6, IL-10,
MMP-1, RANKL, and OPG.The histograms summarize the mean ± SD of the ten independent experiments. ∗𝑝 < 0.05 versus untreated cells.
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(Figure 6) and, interestingly, this inhibition was maintained
even in RA-FLSs exposed to SF, whereMMP1 levels were very
high.
Other authors have shown that IAP antagonists may
induce high turnover osteoporosis characterized by enhanced
osteoclast and osteoblast activities in mice and may increase
the risk of tumour growth and metastasis in the bone
by stabilizing NF-𝜅B inducing kinase (NIK) and activating
the alternative NF-𝜅B pathway in osteoclasts [39]. There-
fore, we sought to find whether the RANKL/OPG path-
way was altered by Smac127, both in cells cultured in
tissue medium and in the presence of SF. As expected,
RANKL is upregulated in cells cultured in the presence
of SF, but we found no statistically significant difference
in RANKL secretion after the addition of Smac127. Simi-
larly, this compound was not able to influence the OPG
production.
In conclusion, Smac127 demonstrated to be effective
in inducing apoptosis in RA-FLSs which are character-
ized by resistance to apoptosis and are responsible for
the erosive pannus typical of RA. We also demonstrated
that Smac127 has a beneficial regulatory effect on the
expression of proinflammatory cytokines and downregulates
the production of MMPs. We did not confirm previous
observations regarding a possible side effect on bone due
to upregulation of RANKL and downregulation of OPG.
Overall, these observations suggest a potential use of Smac
mimetic compounds in general, and Smac127 in particular,
for the control of inflammation and disease progression in
RA.
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